Lexicon Pharmaceuticals, Inc. (LXRX) fundamentals score
Lexicon Pharmaceuticals is a biopharmaceutical company with a mission of pioneering medicines that transform patients’ lives. It is devoting most of its resources to the research and development of its most advanced drug candidates and the commercialization of its approved drug, INPEFA (sotagliflozin):
Pharmaceutical Preparations · Healthcare · Listed on NASDAQ
Overall: 3.6 out of 10, Weak long-term fundamentals
- Growth: 3.2/10
- Profitability: 3.3/10
- Financial health: 5.5/10
- Earnings quality: 3.5/10
- Valuation: 2.5/10
Scores are calculated from Lexicon Pharmaceuticals, Inc.’s SEC filings, using the 12 months through 2026-06. Compare it with past big winners, check its flags, and see today’s price against its fundamentals in the full scorecard.
Other Healthcare stocks
- Nurix Therapeutics, Inc. (NRIX): 9.0/10
- Caredx, Inc. (CDNA): 8.9/10
- Dexcom, Inc. (DXCM): 8.8/10
- Exelixis Inc. (EXEL): 8.8/10
- Neurocrine Biosciences Inc. (NBIX): 8.7/10
- Progyny, Inc. (PGNY): 8.6/10
- Healthcare Services Group, Inc. (HCSG): 8.5/10
- Insulet Corporation (PODD): 8.5/10